CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies

54Citations
Citations of this article
84Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The substantial advances attained by checkpoint blockade immunotherapies have driven an expansion in the approaches used to promote T cell access to the tumor microenvironment to provide targets for checkpoint immunotherapy. Inherent in any T cell response to a tumor antigen is the capacity of dendritic cells to initiate and support such responses. Here, the rationale and early immunobiology of CD40 as a master regulator of dendritic cell activation is reviewed, with further contextualization and appreciation for the role of CD40 stimulation not only in cancer vaccines but also in other contemporary immune-oncology approaches.

Author supplied keywords

Cite

CITATION STYLE

APA

Bullock, T. N. J. (2022, January 1). CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cellular and Molecular Immunology. Springer Nature. https://doi.org/10.1038/s41423-021-00734-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free